ClinConnect ClinConnect Logo
Search / Trial NCT06675539

Validation of the French Version of the Prediction of the Alcohol Withdrawal Severity Scale (PAWSS)

Launched by ETABLISSEMENT PUBLIC DE SANTÉ BARTHÉLEMY DURAND · Nov 4, 2024

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Alcohol Use Disorder Scale Alcohol Withdrawal Prediction Withdrawal Syndrome

ClinConnect Summary

This clinical trial is focused on testing a French version of a tool called the Prediction of Alcohol Withdrawal Severity Scale (PAWSS). This tool helps doctors predict how severe a patient's alcohol withdrawal symptoms might be. The main goal of the study is to see if the French version works as well as the original English version for patients dealing with alcohol use disorders.

To participate in this study, individuals need to be between 18 and 60 years old, have a diagnosis of alcohol use disorder, and be hospitalized for alcohol withdrawal or related issues. Participants will be asked to fill out several questionnaires over a three-day hospital stay. These questionnaires will help researchers understand how their symptoms change and how well the French PAWSS works. It’s important to know that certain people, such as those who cannot understand the questions or are scheduled to leave the hospital soon, won't be eligible to join. Overall, this study aims to improve how healthcare providers assess and manage alcohol withdrawal in French-speaking patients.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Male or female, aged 18 to 60 years
  • Subjects with DSM-5 criteria for alcohol use disorders (AUD)
  • Subjects hospitalized for scheduled withdrawal or patients developing alcohol withdrawal hospitalized for another reason.
  • Subjects who understand French
  • Subject affiliated to the French social security system
  • Subject having given their written consent to the study
  • Exclusion Criteria:
  • Subjects transferred from other hospitalization services for whom a withdrawal syndrome could have already been treated.
  • Subjects scheduled for discharge within 48 hours.
  • Subjects with known uncontrolled epilepsy.
  • Subjects unable to understand the questionnaire.
  • Subjects unable to give consent or not volunteering for the study.
  • Subjects under guardianship or curatorship.

About Etablissement Public De Santé Barthélemy Durand

L'Établissement Public de Santé Barthélemy Durand is a prominent healthcare institution dedicated to advancing medical research and improving patient care through innovative clinical trials. With a focus on multidisciplinary collaboration, the establishment fosters an environment that prioritizes patient safety, ethical standards, and scientific rigor. It aims to contribute to the development of new therapeutic strategies and enhance healthcare outcomes, all while ensuring compliance with regulatory guidelines and promoting community health initiatives.

Locations

étampes, , France

Patients applied

0 patients applied

Trial Officials

Alain Dervaux

Principal Investigator

Etablissement Public de Santé Barthélemy Durand

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported